Evelo Biosciences, Inc.

The call did not provide quarterly revenue, EPS, gross margin, or a full P&L. Reported hard figures included $79.2 million raised in a registered direct offering in May 2022 and a $45 million debt refinancing with Horizon Technology Finance in December 2022. On clinical data, EDP1815’s Phase 2 mild-to-moderate psoriasis study previously showed PASI-50 or greater responses of 25% to 32% versus 12% for placebo, with statistical significance at P value less than 0.05 in active cohorts. For atopic dermatitis, management said it is looking for around 40% EASI-50 or greater on active treatment versus placebo separation of 15% in the fourth cohort. For EDP2939 psoriasis, safety was cleared in healthy volunteers and Phase 2 data are expected in the second half of 2023. Management said cash preservation steps and prioritization would focus spending on the two key clinical programs this year, but they did not give a specific cash burn number.

Simba Gill framed 2022 as a year of scientific and regulatory progress, with the core message that Evelo is translating its SINTAX biology into a new EV-based drug class. He stressed that EDP2939 builds on EDP1815 proof-of-concept but could deliver better efficacy while preserving the placebo-like safety profile seen previously. His tone was optimistic but cautious, repeatedly tying the Phase 3 path for EDP1815 to financing and emphasizing active partnership discussions as a prerequisite for broader execution.

Marella Thorell focused on capital and spend discipline, saying the company had already preserved cash and would prioritize investment in the two key clinical programs and milestones for the year. She highlighted the company’s financing actions: $79.2 million raised in May 2022 and a $45 million debt refinancing in December 2022. She did not provide a detailed burn forecast or margin discussion on the call.

Analysts pressed management on the high placebo response in atopic dermatitis, whether the fourth cohort could be modified, and what could be ruled out; management said it had engaged sites closely to ensure protocol adherence and had essentially ruled out a drug/placebo supply mix-up. Questions also focused on what efficacy bar would define success for EDP2939 and what the lower-dose rationale was; management said it is looking for Otezla-like efficacy or better with strong safety, and that the Phase 2 dose selection was intentionally conservative, based on pharmacology and potency. Another question addressed whether EDP1815 would move forward if financing or a partnership is secured; management said it is still working through that decision and did not commit to timing.